A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Recruiting
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Clinical Advancement Ctr, PLLC, San Antonio, Texas +1 locations
Conditions: Chronic Kidney Disease
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Recruiting
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
08/08/2025
Locations: Texas Diabetes Institute, San Antonio, Texas
Conditions: Obesity
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: DM Clinical Research, San Antonio, Texas
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
Recruiting
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: Ascletis Clinical Site, San Antonio, Texas
Conditions: Chronic Weight Management
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Recruiting
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: University Health - Texas Diabetic Institute, San Antonio, Texas +1 locations
Conditions: Spinal Cord Injuries, Type 2 Diabetes
Prevention of Progression of Prediabetes, Obesity and CV Risk
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases